ViaDerma, Inc. (VDRM)

ViaDerma, Inc. (VDRM) — VMCI valuation read

Headline read on VDRM: VMCI of 43/100 versus a Healthcare sector median of 50. The 7-point below-median position is what makes ViaDerma, Inc. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on VDRM: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on VDRM: value (VDRM trades at 23.0x earnings, 28% above the Healthcare median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 0.6x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

VDRM fell 3.0% over the trailing 7 days, with a -21.6% read on a 30-day basis.